The Principal Investigator in this proposal is an M.D., Ph.D. post-doctoral fellow subspecializing in endocrinology who is interested in becoming an independent translational genomics investigator. He plans to extend the findings of diabetes genetics research into the clinical arena, and thus contribute to understand the heterogeneity of type 2 diabetes (T2DM), the impact of common genetic variation on the development of diabetes and the role of an individual's genetic profile in therapeutic response. In order to do so, he is currently training in Dr. David Altshuler human genetics laboratory at the Massachusetts General Hospital (MGH), which has intellectual and technological ties to the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research. He is also sponsored by Dr. David Nathan, the head of the MGH Diabetes Center and an international leader in diabetes clinical trials. This proposal aims to study the role of common variation in genes encoding drug targets for T2DM. Type 2 diabetes is a polygenic disease, and recent evidence has implicated single nucleotide polymorphisms (SNPs) in the peroxisome proliferator-activated receptor-gamma (PPARG, a target for thiazolidinediones) and the sulfonylurea receptor complex in the pathogenesis of the disease. A T2DM association of common variants in AMP kinase (a presumed drug target for metformin) has not been reported. During the initial phase of the project, the haplotype structure of the genes for the sulfonylurea receptor, its associated potassium channel and the five known subunits of AMP kinase will be elucidated. Haplotype tag SNPs will be tested for association with T2DM in several family-based and case-control panels totalling 7000 subjects. The role of any associated SNPs and the Pro12Ala variant in PPARG in the development of T2DM and the response to various drugs will be studied in the Diabetes Prevention Program patient sample. In collaboration with Dr. Deirdre Blake, the impact of genetic variation in the above genes on response to short-term therapy will be measured by studying multiple parameters of human beta cell function. Finally, whether variability in long-term response to hypoglycemic therapy can be observed in clinical practice will be determined in a clinical study. This proposal should serve as the foundation for a large pharmacogenomics trial designed to evaluate the feasibility of genetically-tailored therapy in T2DM.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
Application #
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Hyde, James F
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Dauriz, Marco; Porneala, Bianca C; Guo, Xiuqing et al. (2015) Association of a 62 Variants Type 2 Diabetes Genetic Risk Score With Markers of Subclinical Atherosclerosis: A Transethnic, Multicenter Study. Circ Cardiovasc Genet 8:507-15
Wessel, Jennifer; Chu, Audrey Y; Willems, Sara M et al. (2015) Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nat Commun 6:5897
Lemaitre, Rozenn N; Johnson, Catherine O; Hesselson, Stephanie et al. (2014) Common variation in fatty acid metabolic genes and risk of incident sudden cardiac arrest. Heart Rhythm 11:471-7
Lee, C Christine; Haffner, Steven M; Wagenknecht, Lynne E et al. (2013) Insulin clearance and the incidence of type 2 diabetes in Hispanics and African Americans: the IRAS Family Study. Diabetes Care 36:901-7
Grimsby, Jonna L; Porneala, Bianca C; Vassy, Jason L et al. (2012) Race-ethnic differences in the association of genetic loci with HbA1c levels and mortality in U.S. adults: the third National Health and Nutrition Examination Survey (NHANES III). BMC Med Genet 13:30
de Miguel-Yanes, Jose M; Shrader, Peter; Pencina, Michael J et al. (2011) Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care 34:121-5
Manning, Alisa K; LaValley, Michael; Liu, Ching-Ti et al. (2011) Meta-analysis of gene-environment interaction: joint estimation of SNP and SNP × environment regression coefficients. Genet Epidemiol 35:11-8
Voight, Benjamin F; Scott, Laura J; Steinthorsdottir, Valgerdur et al. (2010) Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 42:579-89
Saxena, Richa; Hivert, Marie-France; Langenberg, Claudia et al. (2010) Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 42:142-8
Yang, Quanhe; Liu, Tiebin; Shrader, Peter et al. (2010) Racial/ethnic differences in association of fasting glucose-associated genomic loci with fasting glucose, HOMA-B, and impaired fasting glucose in the U.S. adult population. Diabetes Care 33:2370-7

Showing the most recent 10 out of 45 publications